The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
Data released by the federal government has highlighted the widening gap between fully vaccinated Indigenous Australians and the overall population, and the direct impact COVID-19 will have on First Nations people if Australia eases restrictions once 70 or 80 per cent of adults are vaccinated.
Historically, Australia’s Aboriginal community has been heavily impacted by the effects of widespread viral infections such as measles, smallpox and the Spanish Flu and this article highlights the impact low COVID-19 vaccination rates could have on our First Nations people.
Despite the slow rollout, Victoria is leading the way in terms of vaccination rates amongst the Indigenous population with 43% of people fully vaccinated against COVID-19, more than double that of the non-Indigenous population in Victoria at 26%.
According to Jeroen Weimar, the COVID-19 response commander in Victoria, the states’ success with facilitating a competent roll out initiative amongst the Indigenous communities can be attributed to joint efforts and strong partnerships.
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें।
The Age: ‘The moment you walk in through those doors your healing starts’: Victoria leading the race on Indigenous vaccination
WHO: Safety profile of nOPV2 vaccine
In an attempt to implement a global eradication initiative of the polio virus, the first type 2 novel oral polio vaccine (nOPV2) became the first vaccine to be authorised for use under the WHO Emergency Use Listing (EUL) apparatus. However, the current nOPV2 vaccine presents an increased risk of type 2 circulating vaccine-derived polioviruses (cVDPV2), especially in communities with low immunization rates. African countries continue to be amongst the most impacted by this potentially lethal virus. Consequentially, the use of the nOPV2 is currently restricted and SAGE recommended that an independent safety monitoring group be established (GACVS) and maintain thorough safety observations during the entire period of the EUL.
Under the current EUL, there is a 2 phase roll out of the nOPV2 vaccine. With phase 1, countries must first meet stringent initial use criteria and verification requirements including continuous flaccid paralysis (AFP) monitoring to attain approval for use. Following this, phase 2 supports the use of the nOPV2 vaccine as a standard response for cVDPV2 outbreaks.
Following rigorous safety criteria, as of 9 June 2021, 7 countries have received approval for use authorisation of the nOPV2 vaccine and 25 countries are still pending. Majority of the nOPV2 doses thus far have been administered in Nigeria (17 899 130) and Liberia (853 279) amongst children 5 years of age and under in the form of two oral vaccine drops. GACVS is working closely with the Liberian and Nigerian governments to implement AESI surveillance and ongoing AFP data to ensure the safety and effectiveness of the vaccine in preventing polio infection. Current preliminary data analysis did not indicate elevated safety issues associated with the nOPV2 vaccine, however GACVS members have stressed that prolonged, comprehensive surveillance is imperative to signal imminent safety concerns.
To read the extract in full, please click on the link below:
WHO: Safety profile of nOPV2 vaccine
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
अमेरिकी खाद्य एवं औषधि प्रशासन (एफडीए) ने 16 वर्ष से अधिक उम्र के लोगों के लिए फाइजर कोविड-19 वैक्सीन की पूर्ण मंजूरी के बाद सलाह जारी की है कि इसे छोटे बच्चों को ऑफ-लेबल उपयोग के रूप में नहीं दिया जाना चाहिए।
Pfizer's COVID-19 vaccine was 12 से 15 वर्ष की आयु के बच्चों में उपयोग के लिए अधिकृत मई में एफडीए द्वारा, ईयूए में संशोधन के सभी मानदंडों को पूरा करते हुए और 12-15 आयु वर्ग के बच्चों में 1001टीपी3टी प्रभावशीलता के साथ। इसके अतिरिक्त, मॉडर्ना और जॉनसन एंड जॉनसन दोनों टीके अमेरिका में 18 वर्ष और उससे अधिक उम्र के किसी भी व्यक्ति के लिए उपलब्ध हैं, मॉडर्ना अभी भी एफडीए के साथ आपातकालीन उपयोग प्राधिकरण पर अनुमोदन के निर्णय का इंतजार कर रही है।
5-11 साल के बच्चों पर फाइजर वैक्सीन सुरक्षा डेटा सितंबर के अंत तक प्रस्तुत किया जाना है, मॉडर्ना की रिपोर्ट गिरावट के बीच में आने वाली है। क्लिनिकल परीक्षण अभी भी चल रहे हैं, हालांकि, यह उम्मीद की जाती है कि 5-11 वर्ष की आयु के बच्चों के लिए पहला टीका 2021 के अंत तक या 2022 की शुरुआत में हो सकता है। रोल आउट शुरू होने से पहले दुर्लभतम दुष्प्रभावों का पता लगाने के लिए अमेरिका, एफडीए ने सलाह दी है कि परीक्षणों के लिए स्वयंसेवकों के पूल का विस्तार करने की आवश्यकता होगी।
लेख को पूरा पढ़ने के लिए कृपया नीचे दिए गए लिंक पर क्लिक करें
एबीसी न्यूज यूएस: अधिकारी का कहना है कि एफडीए द्वारा अनुमोदित फाइजर वैक्सीन बच्चों में ऑफ-लेबल उपयोग के लिए ठीक नहीं है
MVEC animation: Myocarditis, pericarditis and COVID-19 vaccines
MVEC have created a new animation to help explain myocarditis and pericarditis which have been reported in a small number of individuals who have received mRNA कोविड-19 टीके Comirnaty™ और Moderna.
To view the animation and to find out more information, please refer to our myocarditis, pericarditis following COVID-19 mRNA vaccines immunisation reference page:
MVEC animation: Myocarditis and pericarditis following COVID-19 mRNA vaccines